Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Although the aetiology of SSc-PAH remains elusive, vascular dysfunction seems to be the
initial event and statins through their vasculoprotective effect might be of value in the
treatment armamentarium of PAH related to SSc.
The aim was to assess the efficacy of rosuvastatin in ameliorating vascular dysfunction and
in the management of SSc-related PAH.
Phase:
Phase 3
Details
Lead Sponsor:
Faculty of Medicine, University of Alexandria University of Alexandria